Novo Nordisk A/S (NVO) Earnings

Novo Nordisk A/S

NVO · NYSE

Sep 2026upcoming

Next quarter

Reports Nov 4, 2026, before the open.

Consensus is $0.81 EPS for Sep 2026 across 4 estimates, ranging $0.75 to $0.86.

NVO Jun 2026

Reported Aug 4, 2026

: 17.07%
: +0.56%

: $0.82
: $0.96
: —
: —

Our read on this quarter has not been written yet. The filed figures and the source documents are above and below.

Symbol: NVO
Type: Stock
Sector: Health Care
Industry: Biotechnology: Pharmaceutical Preparations
Country: Europe
Exchange: NYSE

Novo is the global healthcare company that believes lasting health starts now. For over a century, we've combined leading scientific expertise with a deep understanding of people's lives. We develop treatments and support that help millions of people make progress they can see, feel and sustain now and in the future. Every day, over 67,000 employees around the world advance our purpose to drive change for lasting health. Through our partnerships, programmes and investments, we're working to prevent disease, expand access to treatments and reduce our environmental impact to help even more people live healthier lives.

Key Issues

Bullish view

Novo plans to expand its lineup and pipeline by 2030, with the aim of serving far more patients.

Bearish view

Lilly reported a Q3 earnings and sales beat driven by Mounjaro and Zepbound and raised its 2026 revenue outlook to $91-$92 billion, underscoring a strong competitor in obesity and diabetes medicines.

Analyst Consensus

See all

Underperform

13 analysts

$40

Current

—

Low

$42

Average

—

High

Average target implies +5.11% versus the current price.

Earnings History

BeatMissNo estimate

Peers

Pfizer, Inc.PFE · NYSE